DIAM Spinal Stabilization System
Companion Spine France Sas · Decision date Dec 10, 2025
What did the FDA approve?
FDA records P240043 as an original PMA application. The recorded decision is approval, dated Dec 10, 2025.
FDA approval order statement
The DIAM Spinal Stabilization System is indicated for skeletally mature patients that have moderate to severe primary low back pain (greater than leg pain) secondary to lumbar degenerative disc disease (DDD), at a single level from L2-L5 with current episode refractory to at least 6 months of non-operative care.Symptomatic disc disease is confirmed by patient history, physical examination, and radiographic evaluation with one or more of the following factors: Greater than 2mm of decreased disc height (average disc height) compared to the adjacent level Scarring/thickening of the ligamentum flavum, annulus fibrosus, or facet joint capsule Non-extruded herniated nucleus pulposusThe DIAM device is implanted via a minimally invasive posterior approach.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Orthopedic
- Decision date
- Dec 10, 2025
Regulatory record facts
- Identifier
- P240043
- Regulatory pathway
- Premarket approval application
- Applicant
- Companion Spine France Sas
- Product code
- NQO
- Decision code
- APPR
- Decision date
- Dec 10, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, spinous process spacer/plate.
- Applicant
- Companion Spine France Sas
- Product code
- NQO
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240043 received
Application receipt date recorded by FDA.
P240043 · FDA decision
APPR
P240043/S001 · Related supplement
DIAM Spinal Stabilization System
Timeline entries are records held by MedtechLedger for P240043. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240043
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
DIAM Spinal Stabilization SystemP240043/S001 | Companion Spine France Sas | PMA supplement | Apr 1, 2026 | FDA |
Explore the linked device profile
Other records with product code NQO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
coflex Interlaminar TechnologyP110008/S015 | Companion Spine France | PMA supplement | May 22, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Companion Spine France Sas
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Immeuble Le Bridge 5, 5 Allee Des Acacias, Merignac, 33 700
Sources and methodology
- Original FDA record: P240043
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
